Search review questions

Length/height‐for‐age z‐score (L/HAZ)b · children under 5 years of age

Stuntingb · children under 5 years of age

Adverse effect: hypercalciuria As defined by trialists Time frame: 3 months · children under 5 years of age

Adverse effect: hypercalcaemia As defined by trialists Time frame: 2.2 months (mean) · children under 5 years of age

Length/height‐for‐age z‐score (L/HAZ) Time frame: 6 months · children under 5 years of age

Adverse effect: hyperphosphataemiab · children under 5 years of age

Adverse effect: kidney stonesb · children under 5 years of age

Stunting Definition: L/HAZ < ‐2Time frame: 6 months · children under 5 years of age

Adverse effect: hypercalciuria As defined by trialistsTime frame: 6.5 months (mean) · children under 5 years of age

Adverse effect: hypercalcaemia As defined by trialistsTime frame: 7.5 months (mean) · children under 5 years of age

Adverse effect: hyperphosphataemiae · children under 5 years of age

Adverse effect: kidney stonese · children under 5 years of age

Linear growth (length/height) Unit: cm Time frame: 4.2 months (mean) · children under 5 years of age

Length/height‐for‐age z‐score (L/HAZ) Unitless Time frame: 7 months (mean) · children under 5 years of age

BPD symptom severity Measured by: clinicians and self‐rated Timing of outcome assessment: end of treatment · borderline personality disorder

Suicide‐related outcomes Measured by: self‐rated Timing of outcome assessment: end of treatment · borderline personality disorder

Psychosocial functioning Measured by: clinicians and self‐rated Timing of outcome assessment: end of treatment · borderline personality disorder

Depression Measured by: clinicians and self‐rated Timing of outcome assessment: end of treatment · borderline personality disorder

Attrition Timing of outcome assessment: end of treatment · borderline personality disorder

Adverse effects (not measured · borderline personality disorder

DBT · borderline personality disorder

BPD severity Measured by: clinicians Timing of outcome assessment: end of treatment · borderline personality disorder

Self‐harm Measured by: clinicians Timing of outcome assessment: end of treatment · borderline personality disorder

Psychosocial functioning Measured by: clinicians and self‐rated Timing of outcome assessment: end of treatment · borderline personality disorder

MBT · borderline personality disorder

Self‐harm (frequency) Measured by: clinicians and self‐rated Timing of outcome assessment: end of treatment · borderline personality disorder

Suicide‐related outcomes Measured by: clinicians Timing of outcome assessment: end of treatment · borderline personality disorder

Suicide‐related outcomes (suicidality) Measured by: clinicians and self‐rated Timing of outcome assessment: end of treatment · borderline personality disorder

Psychosocial functioning Measured by: clinicians and self‐rated Timing of outcome assessment: end of treatment · borderline personality disorder

Depression Measured by: clinicians and self‐rated Timing of outcome assessment: end of treatment · borderline personality disorder

Attrition Timing of outcome assessment: end of treatment · borderline personality disorder

Adverse effects Timing of outcome assessment: end of treatment · borderline personality disorder

BPD symptom severity Measured by: clinicians and self‐rated Timing of outcome assessment: end of treatment · borderline personality disorder

Self‐harm Measured by: clinicians and self‐rated Timing of outcome assessment: end of treatment · borderline personality disorder

Mobility Measured by: walking speed on a Biodex Gait Trainer 2™ (average speed over 3 × 3 minutes, reported in m/s) Timing of outcome assessment: change scores from baseline to 12 weeks · children with cerebral palsy classified within GMFCS Levels I to III between 5 and 19 years of age

Quality of life (not measured) · children with cerebral palsy classified within GMFCS Levels I to III and between 3 and 12 years of age

Mobility Measured by: 10‐meter walk test or 8‐meter walk test (walking speed over a short distance; greater speed = greater functional mobility), reported in m/s Timing of outcome assessment: change scores from baseline to 2 to 12 weeks or postint... · children with cerebral palsy classified within GMFCS Levels I to V and between 3 and 18 years of age

Gross motor function Measured by: GMFM‐E (higher score = greater performance), reported as % Timing of outcome assessment: change scores from baseline to 4 to 12 weeks or postintervention scores at 4 to 12 weeks · children with cerebral palsy classified within GMFCS Levels I to V and between 3 and 18 years of age

Adverse events Measured by: no official measure; instead events are reported from observation Timing of outcome assessment: postintervention reports at 2 to 6 weeks · children with cerebral palsy classified within GMFCS Levels I to V and between 3 and 18 years of age

Participation Measured by: CAPE‐intensity score or WeeFIM score; higher scores = greater participation Timing of outcome assessment: change scores from baseline to 2 to 12 weeks · children with cerebral palsy classified within GMFCS Levels I to V and between 3 and 18 years of age

Quality of life Measured by: PedsQOL‐CP score (range from 0 to 100; higher scores = better quality of life) Timing of outcome assessment: change scores from baseline to 12 weeks · children with cerebral palsy classified within GMFCS Levels I to V and between 3 and 18 years of age

Mobility Measured by: 10‐meter walk test (walking speed over a short distance; greater speed = greater functional mobility) or 6‐minute walk test (distance in meters walked in 6 minutes; greater distance = greater endurance), reported in m/s Timin... · children with cerebral palsy classified within GMFCS Levels I to IV and between 4 and 18 years of age

Gross motor function Measured by: GMFM‐E (higher score = greater performance), reported as % Timing of outcome assessment: postintervention scores at 8 to 10 weeks · children with cerebral palsy classified within GMFCS Levels I to IV and between 4 and 18 years of age

Adverse events (not measured) · children with cerebral palsy classified within GMFCS Levels I to IV and between 4 and 18 years of age

Participation Measured by: SFA score (total scores range from 19 to 76; higher scores = greater participation) Timing of outcome assessment: change scores from baseline to 10 weeks · children with cerebral palsy classified within GMFCS Levels I to IV and between 4 and 18 years of age

Gross motor function Measured by: PDMS‐2‐locomotion (higher score = greater performance, reported as score) or mTUG (higher score = greater performance, reported in ‐seconds) Timing of outcome assessment: postintervention scores at 12 weeks · children with cerebral palsy classified within GMFCS Levels I to III between 5 and 19 years of age

Quality of life (not measured) · children with cerebral palsy classified within GMFCS Levels I to IV and between 4 and 18 years of age

Adverse events Measured by: no official measure; instead events are reported from observation Timing of outcome assessment: postintervention reports at 12 weeks · children with cerebral palsy classified within GMFCS Levels I to III between 5 and 19 years of age

Participation (not measured) · children with cerebral palsy classified within GMFCS Levels I to III between 5 and 19 years of age

Quality of life (not measured) · children with cerebral palsy classified within GMFCS Levels I to III between 5 and 19 years of age